.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
Erdheim-Chester disease (ECD) is a multisystemic histiocytic neoplasm often identified by skeletal and visceral involvement. However, recent medical literature emphasizes the importance of recognizing atypical Erdheim-Chester disease skin lesions. Specifically, some patients develop glomeruloid haemangiomas and extensive angiomas. These lesions occur even when the classic features of POEMS syndrome are absent. Investigators have linked these findings to markedly elevated levels of vascular endothelial growth factor-A (VEGF-A).
Research demonstrates that MAPK-activated histiocytes drive these skin changes through a paracrine mechanism. Molecular analyses show that the histiocytes themselves harbor the activating mutations rather than the endothelial cells. Consequently, these histiocytes secrete VEGF-A, which stimulates localized blood vessel growth. This unique pathway explains why vascular proliferations appear in these patients. Furthermore, this mechanism differentiates these lesions from those caused by intrinsic vascular mutations.
Notably, the presence of glomeruloid haemangiomas often suggests POEMS syndrome. However, in the context of ECD, these lesions emerge due to systemic cytokine elevations. Clinicians should therefore screen patients with atypical vascular lesions for underlying histiocytic disorders. Treatment often targets the underlying MAPK pathway using BRAF or MEK inhibitors. Monitoring VEGF-A levels may also provide insight into disease activity and treatment response.
The most common skin findings are periorbital xanthelasma-like lesions. However, atypical vascular lesions like glomeruloid haemangiomas can occur due to high VEGF-A levels.
Histiocytes with MAPK mutations produce VEGF-A. This factor acts on nearby blood vessels to cause abnormal proliferation, leading to angiomas in the skin.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or a professional relationship. Refer to the latest local and national guidelines for clinical practice.
References
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
Recent studies reveal that Erdheim-Chester disease can manifest as glomeruloid haemangiomas driven by elevated VEGF-A levels. This discovery highlights a paracrine mechanism involving MAPK-activated histiocytes, providing new insights into the atypical cutaneous manifestations of this rare histiocytic neoplasm.
2 months ago
A breakthrough study using human colonic organoids demonstrates that bacterial serine protease EspP, an EHEC cytotoxin, halts epithelial proliferation and preferentially triggers enteroendocrine cell differentiation, promoting pro-inflammatory chemokine release and immune cell recruitment.
Yesterday
Recent research reveals that downregulating YAP1/TAZ-TEAD via Hippo signaling triggers spontaneous human trophoblast syncytialization in 3D cultures, illuminating placental biology and preeclampsia.
Yesterday
A landmark comparative study evaluates atrial electrophysiology across humans, swine, and rodents. By linking cellular recordings with transcriptomics and in silico modeling, researchers resolve cross-species gaps, explaining translational failures to advance targeted therapies for atrial arrhythmias.
Yesterday
A novel pathology-adaptive surface engineering strategy uses functionalized plasma polymer coatings to selectively modulate AGE adsorption, reducing oxidative stress and restoring bone formation in diabetic and aging microenvironments.
4 weeks back
Researchers have developed an innovative ultrasound-responsive nano-contrast agent that co-delivers CIITA-siRNA and rapamycin directly to inflamed thyroid tissue, significantly reducing autoimmune injury and thyroid autoantibodies in preclinical models of Hashimoto thyroiditis.
Yesterday
